Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Kezar Life Sciences, a clinical-stage biotechnology firm, has announced participation in two investor conferences this November. The Jefferies London Healthcare Conference will feature Dr. Noreen Roth Henig on November 16, 2022, at 8:35 AM GMT. The Evercore ISI HealthCONx Conference will include CEO John Fowler on November 30, 2022, at 12:10 PM ET. Both presentations will be available via webcast on their website for 90 days post-event. The company focuses on treatments for immune-mediated and oncologic disorders, notably their lead asset, Zetomipzomib.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November.

Presentation Details:

Event: Jefferies London Healthcare Conference
Location: London, UK
Date/Time: Wednesday, November 16, 2022, at 8:35 AM GMT
Presenter: Noreen Roth Henig, M.D., Chief Medical Officer
Format: Fireside Chat

Event: Evercore ISI 5^th Annual HealthCONx Conference
Location: Boston, MA
Date/Time: Wednesday, November 30, 2022, at 12:10 PM ET
Presenters: John Fowler, Co-Founder, Chief Executive Officer
Format: Fireside Chat

Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005819/en/

Investor Contact:

Gitanjali Jain

Vice President, Investor Relations and External Affairs

gjain@kezarbio.com

Media Contact:

Julia Deutsch

Solebury Strategic Communications

jdeutsch@soleburystrat.com

Source: Kezar Life Sciences, Inc.

FAQ

What conferences is KZR participating in November 2022?

Kezar Life Sciences is participating in the Jefferies London Healthcare Conference on November 16, 2022, and the Evercore ISI HealthCONx Conference on November 30, 2022.

Who will present at the Jefferies London Healthcare Conference?

Dr. Noreen Roth Henig, Chief Medical Officer, will present at the Jefferies London Healthcare Conference.

When is KZR's presentation at the Evercore ISI HealthCONx Conference?

Kezar Life Sciences' presentation at the Evercore ISI HealthCONx Conference is scheduled for November 30, 2022, at 12:10 PM ET.

What is the lead asset of KZR?

Kezar Life Sciences' lead asset is Zetomipzomib, a selective immunoproteasome inhibitor being evaluated for lupus nephritis.

Where can I find the webcasts of KZR's presentations?

Webcasts of Kezar Life Sciences' presentations will be available on their website in the 'Events & Presentations' section.